Alcon takes majority stake in Aurion, changes CEOs

Eye giant Alcon said Wednesday it acquired a majority stake in cell therapy startup Aurion and replaced CEO Greg Kunst, the latest twist in a struggle for power between the two companies. The Seattle-based biotech ...

Related Posts

Roche sends experimental CNS drugs to Newleos, a new bi...

Feb 13, 2025  0

Novo's weight loss drug helps curb some drinking habits...

Feb 12, 2025  0

Chinese ADC biotech lets Hong Kong IPO filing lapse

Feb 25, 2025  0

Comments

Name

Email

Comment

Post Comment